| 摘要 |
The invention relates to the discovery of a human endogenous retrovirus (HERV) family, Type I HERV-K (HML-2) which appear to be active in vitro and in vivo, infectious, and which have the have the salient features and properties of foamy retroviruses. Based on its natural replication in humans, and that it protects the host from viral and tumor transformation, this non-pathogenic endogenous virus could be developed as a replication competent gene therapy vector. It also is expected to have much higher efficacy than other vectors as it crosses the bloodbrain barrier and infects almost all cell types in the host (proliferating or not). It may naturally lyse tumor cells or infected cells, and thus could even be used without genetic modification. Of course, this vector could be used in traditional ways with it ability to replicate genetically removed. In addition to its value as a vector, as it is reactivated with infection, its detection could also be used to monitor the safety of gene therapy (irrespective of vector type used), as well as other biological therapies including vaccination, blood transfusion, transplantation and xenotransplantation. Finally it may be used to screen for new therapeutic and prophylactic treatments for a wide variety of diseases.
|
